Jon Ellis, CEO, Trenchant BioSystems | Onyx Live | ISCT Dublin 2026
Fewer than 10% of eligible CAR-T patients ever get treated. Trenchant BioSystems CEO Jon Ellis says the bottleneck is no longer the science – it's manufacturing.
Fewer than 10% of eligible CAR-T patients ever get treated. Trenchant BioSystems CEO Jon Ellis says the bottleneck is no longer the science – it's manufacturing.